BioSpace News Archive

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that it has submitted an Investigational New Drug (IND) application to U.S. Food and Drug Administration to evaluate its investigational drug, Silmitasertib(CX-4945), for treating patients with community-acquired pneumonia (CAP) caused by viral infection.

Armata Pharmaceuticals, Inc. today announced that its Chief Medical Officer, Mina Pastagia , M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.

STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles to deliver gene therapies and developing new therapeutics for rare blood diseases, announced that CEO Jonathan Thon, Ph.D. is the featured speaker at the 5th annual R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute.

PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream.

Anokion SA announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.

Alnylam Pharmaceuticals, Inc. announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial markets open.

Hummingbird Bioscience and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.

Summit Therapeutics Inc. announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer.

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR).

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”) today announced the presentation of translational data at the 2023 Pittsburgh-Ireland International Lung Conference: Precision Medicine in Lung Diseases: From Cellular Mechanisms to Clinical Phenotypes held October 16-17, 2023 at the RCSI University of Medicine and Health Sciences in Dublin, Ireland.